Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYX NYSE:CATX NASDAQ:CLPT NASDAQ:SNWV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$2.06+1.5%$2.10$0.76▼$2.73$77.91M1.39115,071 shs72,291 shsCATXPerspective Therapeutics$3.56+5.3%$3.77$1.60▼$16.55$264.38M1.17942,412 shs485,170 shsCLPTClearPoint Neuro$10.24-1.3%$11.27$9.76▼$19.22$291.12M0.85318,209 shs214,230 shsSNWVSanuwave Health$41.26+4.6%$35.21$5.21▼$46.58$353.60M1.2952,033 shs41,188 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical+3.05%-13.62%-9.38%+22.29%+58.59%CATXPerspective Therapeutics-1.17%-11.29%-21.58%+34.66%-77.18%CLPTClearPoint Neuro-0.86%-13.00%-5.56%-14.16%-7.90%SNWVSanuwave Health+7.46%-1.08%+2.98%+36.65%+3,944,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPYXApyx Medical1.269 of 5 stars0.03.00.04.20.61.70.6CATXPerspective Therapeutics1.5657 of 5 stars3.61.00.00.01.90.80.0CLPTClearPoint Neuro1.7376 of 5 stars3.51.00.00.01.60.80.6SNWVSanuwave Health0.944 of 5 stars2.50.00.00.00.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate BuyN/AN/ACATXPerspective Therapeutics 3.18Buy$12.56252.68% UpsideCLPTClearPoint Neuro 3.00Buy$19.6792.06% UpsideSNWVSanuwave Health 3.00Buy$49.0018.76% UpsideCurrent Analyst Ratings BreakdownLatest APYX, SNWV, CATX, and CLPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/1/2025CLPTClearPoint NeuroStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.007/29/2025SNWVSanuwave HealthRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$49.007/12/2025CATXPerspective TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.006/3/2025CATXPerspective TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.00(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$48.10M1.62N/AN/A$0.20 per share10.30CATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/ACLPTClearPoint Neuro$31.39M9.27N/AN/A$0.69 per share14.84SNWVSanuwave Health$32.63M10.84N/AN/A($1.72) per share-23.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$23.46M-$0.45N/AN/AN/A-37.11%-158.22%-28.30%11/7/2025 (Estimated)CATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%N/ACLPTClearPoint Neuro-$18.91M-$0.81N/AN/AN/A-66.15%-94.44%-51.58%11/6/2025 (Estimated)SNWVSanuwave Health-$31.37M-$8.25N/A∞N/A-97.03%N/A-135.15%N/ALatest APYX, SNWV, CATX, and CLPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CLPTClearPoint Neuro-$0.20-$0.21-$0.01-$0.21$9.20 million$9.22 million8/8/2025Q2 2025SNWVSanuwave Health-$0.09$0.01+$0.10$0.01$10.14 million$10.16 million8/7/2025Q2 2025APYXApyx Medical-$0.0933-$0.09+$0.0033-$0.09$11.69 million$11.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/ACATXPerspective TherapeuticsN/AN/AN/AN/AN/ACLPTClearPoint NeuroN/AN/AN/AN/AN/ASNWVSanuwave HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical4.614.723.95CATXPerspective TherapeuticsN/A9.609.60CLPTClearPoint Neuro1.467.306.45SNWVSanuwave HealthN/A0.430.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%CATXPerspective Therapeutics54.66%CLPTClearPoint Neuro30.08%SNWVSanuwave Health42.53%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical15.20%CATXPerspective Therapeutics3.72%CLPTClearPoint Neuro6.97%SNWVSanuwave Health14.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27037.82 million32.07 millionOptionableCATXPerspective Therapeutics7074.26 million65.21 millionOptionableCLPTClearPoint Neuro11028.43 million26.45 millionOptionableSNWVSanuwave Health408.57 million7.29 millionN/AAPYX, SNWV, CATX, and CLPT HeadlinesRecent News About These CompaniesSanuwave Health (NASDAQ:SNWV) Releases Earnings Results, Beats Estimates By $0.10 EPSAugust 10, 2025 | marketbeat.comSanuwave Health (NASDAQ:SNWV) Rating Increased to Buy at Wall Street ZenAugust 10, 2025 | marketbeat.comSANUWAVE Health, Inc. (SNWV) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comSanuwave (SNWV) Q2 Revenue Jumps 42%August 8, 2025 | fool.comSanuwave Announces Q2 FY2025 Financial ResultsAugust 8, 2025 | globenewswire.comSanuwave Will Host a Conference Call on August 8, 2025 at 8:30 AM (ET) to Present Q2 2025 Financial ResultsAugust 4, 2025 | globenewswire.comBrokers Issue Forecasts for Sanuwave Health Q2 EarningsAugust 1, 2025 | marketbeat.comRoth Capital Begins Coverage on Sanuwave Health (NASDAQ:SNWV)July 30, 2025 | marketbeat.comSanuwave Health to Present at Canaccord Genuity Growth ConferenceJuly 22, 2025 | globenewswire.comSanuwave: High Growth Wound Care Tech Primed For A BreakoutJune 11, 2025 | seekingalpha.comSanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial OperationsJune 3, 2025 | globenewswire.comSANUWAVE Health, Inc. (SNWV): A Bull Case TheoryMay 29, 2025 | insidermonkey.comSanuwave Health Appoints Greg Bazar to Board of DirectorsMay 28, 2025 | globenewswire.comSanuwave Health Selected for Inclusion in Russell 2000® IndexMay 28, 2025 | globenewswire.comInsider Selling: SANUWAVE Health, Inc. (NASDAQ:SNWV) Insider Sells 3,639 Shares of StockMay 17, 2025 | insidertrades.comSANUWAVE Health, Inc. (SNWV) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comSanuwave Announces Q1 FY2025 Financial ResultsMay 9, 2025 | globenewswire.comSanuwave Will Host a Conference Call on May 9, 2025 at 8:30 AM (ET) to Present Q1 2025 Financial ResultsMay 5, 2025 | globenewswire.comSANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)April 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPYX, SNWV, CATX, and CLPT Company DescriptionsApyx Medical NASDAQ:APYX$2.06 +0.03 (+1.48%) Closing price 04:00 PM EasternExtended Trading$2.00 -0.06 (-3.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Perspective Therapeutics NYSE:CATX$3.56 +0.18 (+5.33%) Closing price 04:00 PM EasternExtended Trading$3.56 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.ClearPoint Neuro NASDAQ:CLPT$10.24 -0.13 (-1.25%) Closing price 04:00 PM EasternExtended Trading$10.26 +0.02 (+0.20%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Sanuwave Health NASDAQ:SNWV$41.26 +1.81 (+4.59%) As of 04:00 PM EasternSANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices and an AI-Driven Semiconductor Supercycle Palantir is Selling Off, BigBear.ai Could Be Your Hedge ASML Has Entered Buy Territory, But Only For Patient Investors Lowe’s Builds Value for Investors: Still a Good Buy in 2025 Target: Missing the Mark in 2025—Downtrend May Continue Toll Brothers: A Great Buy and Hold Stock With Risks in 2025 Amazon Stock Sets Up for Breakout After Bullish Crossover Rocket Lab Stock: Breakout Brewing or Time for Patience? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access